Patents by Inventor Marta Cosenza

Marta Cosenza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY FORMULATION
    Publication number: 20210269540
    Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Application
    Filed: December 18, 2020
    Publication date: September 2, 2021
    Inventors: Marta COSENZA, Christoph HEUSSER, Julia NEUGEBAUER, Eveline SCHAADT, Stefanie URLINGER, Maximilian WOISETSCHLAEGER
  • Anti-BAFFR antibody formulations and methods of use thereof
    Patent number: 10899841
    Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: January 26, 2021
    Assignee: NOVARTIS AG
    Inventors: Marta Cosenza, Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger
  • Anti-BAFFR antibody therapeutic formulations
    Patent number: 10689451
    Abstract: Anti-BAFFR antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: June 23, 2020
    Assignee: Novartis AG
    Inventors: Marta Cosenza, Christoph Stark
  • ANTIBODY FORMULATION
    Publication number: 20190194341
    Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Application
    Filed: March 6, 2019
    Publication date: June 27, 2019
    Inventors: Marta COSENZA, Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximillan Woisetschlaeger
  • Methods of Treatment by Administering an Anti-BAFFR Antibody Therapeutic Formulation
    Publication number: 20180251564
    Abstract: Anti-BAFFR antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Application
    Filed: May 15, 2018
    Publication date: September 6, 2018
    Inventors: Marta COSENZA, Christoph STARK
  • ANTIBODY FORMULATION
    Publication number: 20180179290
    Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant and/or a free amino acid.
    Type: Application
    Filed: February 13, 2018
    Publication date: June 28, 2018
    Inventors: Marta Cosenza, Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger
  • Methods of Treatment by Administering an Anti-BAFFR Antibody Therapeutic Formulation
    Publication number: 20180051092
    Abstract: Anti-BAFFR antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Application
    Filed: August 31, 2017
    Publication date: February 22, 2018
    Inventors: Marta COSENZA, Christoph Stark
  • Methods of treatment by administering an anti-BAFFR antibody therapeutic formulation
    Patent number: 9751951
    Abstract: Anti-BAFFR antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: September 5, 2017
    Assignee: Novartis AG
    Inventors: Marta Cosenza, Christoph Stark
  • ANTIBODY FORMULATION
    Publication number: 20160368999
    Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Application
    Filed: September 1, 2016
    Publication date: December 22, 2016
    Inventors: Marta Cosenza, Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger
  • Anti-BAFFR antibody formulations
    Patent number: 9458240
    Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: October 4, 2016
    Assignee: Novartis Pharma AG
    Inventors: Marta Cosenza, Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger
  • ANTIBODY FORMULATION
    Publication number: 20160145341
    Abstract: Anti-BAFFR antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Application
    Filed: November 16, 2015
    Publication date: May 26, 2016
    Applicant: NOVARTIS AG
    Inventors: Marta Cosenza, Christoph Stark
  • Anti-BAFFR antibody formulation
    Patent number: 9216219
    Abstract: Anti-BAFFR antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: December 22, 2015
    Assignee: Novartis AG
    Inventors: Marta Cosenza, Christoph Stark
  • ANTIBODY FORMULATION
    Publication number: 20140186373
    Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Application
    Filed: December 8, 2011
    Publication date: July 3, 2014
    Inventors: Marta Cosenza, Christoph Heusser, Julia Neugebauer, Eveline Schaadt, Stefanie Urlinger, Maximilian Woisetschlaeger
  • ANTIBODY FORMULATION
    Publication number: 20130344088
    Abstract: Anti-BAFFR antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Application
    Filed: June 7, 2013
    Publication date: December 26, 2013
    Inventors: Marta Cosenza, Christoph Stark